Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

Does prasugrel or ticagrelor suffice in patients with STEMI?

Nature Reviews Cardiology volume 10, pages 121–122 (2013)Cite this article

Subjects

Adequate platelet inhibition early in the course of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention is essential to reduce stent thrombosis and recurrent myocardial infarction. Pharmacodynamic data now suggest that additional platelet inhibition beyond that provided by either prasugrel or ticagrelor might be necessary.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Prasugrel and ticagrelor are more-potent and faster-acting antiplatelet agents than clopidogrel.

References

  1. Yousuf, O. & Bhatt, D. L. The evolution of antiplatelet therapy in cardiovascular disease. Nat. Rev. Cardiol. 8, 547–559 (2011).

    Article  CAS  Google Scholar 

  2. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).

    Article  CAS  Google Scholar 

  3. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).

    Article  CAS  Google Scholar 

  4. Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723–731 (2009).

    Article  CAS  Google Scholar 

  5. Steg, P. G. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122, 2131–2141 (2010).

    Article  Google Scholar 

  6. Alexopoulos, D. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 5, 797–804 (2012).

    Article  CAS  Google Scholar 

  7. Bhatt, D. L. Intensifying platelet inhibition—navigating between Scylla and Charybdis. N. Engl. J. Med. 357, 2078–2081 (2007).

    CAS  Google Scholar 

  8. Heestermans, A. A. et al. Impaired bio-availability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res. 122, 776–781 (2008).

    Article  CAS  Google Scholar 

  9. Bhatt, D. L. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361, 2330–2341 (2009).

    Article  CAS  Google Scholar 

  10. Leonardi, S. et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am. Heart J. 5, 768–776e2 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston Medical Center, 88 East Newton Street, Boston, 02118, MA, USA

    Kush Agrawal

  2. Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital,

    Deepak L. Bhatt

  3. Harvard Medical School, 1400 VFW Parkway, Boston, 02132, MA, USA

    Deepak L. Bhatt

Authors
  1. Kush Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak L. Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak L. Bhatt.

Ethics declarations

Competing interests

D. L. Bhatt has received research grants from the following companies: Amarin, AstraZeneca, Bristol–Myers Squibb, Eisai, Ethicon, The Medicines Company, Medtronic, and Sanofi Aventis; and has performed unfunded research for FlowCo, PLx Pharma, and Takeda. D. L. Bhatt has received honoraria from the American College of Cardiology (as an editor of Clinical Trials and Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (as chief medical editor of Cardiology Today Intervention), and WebMD (CME steering committees). Additionally, D. L. Bhatt is a member of the advisory board of Medscape Cardiology; a member of the board of directors of Boston VA Research Institute and the Society of Chest Pain Centers; and chair of the American Heart Association Get With The Guidelines Science Subcommittee. He is the senior associate editor of the Journal of Invasive Cardiology. D. L. Bhatt served on the steering committee and as a national coordinator of TRILOGY ACS; he serves on the executive committee of PEGASUS TIMI 54; and he is the co-principal investigator of CHAMPION. K. Agrawal declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agrawal, K., Bhatt, D. Does prasugrel or ticagrelor suffice in patients with STEMI?. Nat Rev Cardiol 10, 121–122 (2013). https://doi.org/10.1038/nrcardio.2012.199

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2012.199

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing